Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 

LGP2 (human) polyclonal antibody (AT137)

ALX-210-963-C050 50 µg 304.00 USD
Do you need bulk/larger quantities?

Product Specification

Alternative Name:Protein D11Lgp2 homolog, Probable ATP-dependent RNA helicase DHX58, Probable ATP-dependent RNA helicase LGP2
Immunogen:Synthetic peptide corresponding to 15 aa near the C-terminus of human LGP2.
UniProt ID:Q96C10
Source:Purified from rabbit serum.
Species reactivity:Human
Applications:IP, WB
Recommended Dilutions/Conditions:Immunoprecipitation (1:200)
Western blot (1:1,000)
Suggested dilutions/conditions may not be available for all applications.
Optimal conditions must be determined individually for each application.
Purity Detail:Epitope-affinity purified.
Formulation:Liquid. In PBS containing 0.02% sodium azide.
Use/Stability:Stable for at least 1 year after receipt when stored at -20°C.
Handling:Avoid freeze/thaw cycles. After opening, prepare aliquots and store at -20°C.
Shipping:Shipped on Blue Ice
Short Term Storage:+4°C
Long Term Storage:-20°C
Scientific Background:MDA5 and RIG-I are two key intracellular receptors that recognize virus infection to produce type I IFN. LGP2 is homologous to MDA5 and RIG-I, but lacks the caspase recruitment domain (CARD) crucial for their antiviral activity. LGP2 may be a negative regulator of host innate immune defense against viruses by acting through dsRNA sequestration or inhibition of RIG-I dimerization.
Regulatory Status:RUO - Research Use Only

General Literature References

Negative regulation of cytoplasmic RNA-mediated antiviral signaling: A. Komuro, et al.; Cytokine 43, 350 (2008), Abstract;
Shared and unique functions of the DExD/H-box helicases RIG-I, MDA5, and LGP2 in antiviral innate immunity: M. Yoneyama, et al.; J. Immunol. 175, 2851 (2005), Abstract; Full Text

Recommend this page

Keep in touch

©2020 Enzo Life Sciences, Inc.,